Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Prothena Corporation plc

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Instil Bio, Inc.

Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Prothena Biosciences specializes in developing therapeutics for neurodegenerative and rare peripheral amyloid diseases, focusing on the biology of misfolded proteins.

Metric
Company Name	Prothena Corporation plc	Instil Bio, Inc.
Symbol	PRTA	TIL
MSH ID	COM:PROTHENA	COM:INSTILBIO
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology
Country	IE	US
Stage
Employee Count	173	49
Website	prothena.com	instilbio.com
LinkedIn
Founders

Metric
Market Cap	1.13B	65.10M
Enterprise Value
Monthly Web Traffic		12.72K
Web Traffic Growth		-0.76
Valuation
Raised Capital

Metric
Revenue	91.37M
Revenue (LTM)
Revenue (NTM)
Gross Profit	82.96M
EBITDA	-190.11M
Operating Income	-191.04M
Net Income	-147.03M
EPS	-2.76
Diluted EPS	-2.76
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.92
Operating Profit Margin	-0.42
EBITDA Margin	-2.08
Net Profit Margin	-0.23
Return on Equity	-0.09
Return on Assets	-0.08
Return on Capital Employed	-0.15

COM:PROTHENA

Prothena Biosciences

Last Close

14.44

22/11 21:00

Market Cap

818.97M

Beta: -

Volume Today

468.84K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-18.31
P/B Ratio	2.17
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	14.94
EV Multiple	-7.46

Metric
Days Sales Outstanding	13.36
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle	-184.43
Asset Turnover	0.34

Metric
Operating Cash Flow	-133.91M
Free Cash Flow	-136.72M
Cash Flow to Debt	-8.12
Operating Cash Flow/Sales	-0.45
Free Cash Flow Yield	-0.07

Metric
Cash & Equivalents	620.18M
Accounts Receivable	-5.16M
Inventory	-5.16M
Goodwill
Debt to Capitalization	0.02
Debt to Assets	0.01
Current Ratio	12.94
Quick Ratio	13.08

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.26
R&D to Revenue	1.39
SG&A to Revenue	0.41